Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nasopharyngeal carcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Nasopharyngeal carcinoma. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-001211-33 Sponsor Protocol Number: EFC10339 Start Date*: 2007-06-20
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: International randomized study to evaluate the addition of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF) in the induction treatment of nasopharyng...
    Medical condition: Children and adolescents newly diagnosed with NPC with measurable disease T2-T4 any NM, of <18 years of age at the time of diagnosis. ---------- Niños y adolescentes recien diagnosticados con CNF c...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028793 Nasopharyngeal carcinoma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) GR (Prematurely Ended) FR (Completed) IT (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001745-25 Sponsor Protocol Number: CC-486-NPC-001 Start Date*: 2015-01-22
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Multicenter, International, Single Arm Study to Assess the Safety and Efficacy of Single Agent CC-486 (Oral Azacitidine) in Previously Treated Subjects With Locally Advanced or Metastati...
    Medical condition: Locally advanced or metastatic nasopharyngeal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10028793 Nasopharyngeal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005017-31 Sponsor Protocol Number: DERN Start Date*: 2019-01-29
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: DENOSUMAB IN EBV RELATED NASOPHARYNGEAL CARCINOMA (NPC) AS A MODEL FOR RANK-MEDIATED IMMUNOLOGIC MODULATION OF VIRUS-RELATED TUMOURS – DERN STUDY
    Medical condition: advanced or metastatic Nose Pharynx Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028793 Nasopharyngeal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004649-35 Sponsor Protocol Number: POINT Start Date*: 2021-12-14
    Sponsor Name:Fondazione GONO
    Full Title: Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer
    Medical condition: Nasopharyngeal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028793 Nasopharyngeal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000230-29 Sponsor Protocol Number: CA209-358 Start Date*: 2015-09-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors
    Medical condition: Virus-associated tumors
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046885 Vaginal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061306 Nasopharyngeal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047777 Vulvar cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064025 Merkel cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004939-22 Sponsor Protocol Number: HE 5/06 Start Date*: 2006-05-02
    Sponsor Name:Hellenic Cooperative Oncology Group (HeCOG)
    Full Title: A PHASE I/II EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH RECURRENT OR METASTATIC NON-NASOPHARYNGEAL HEAD AND NECK CANCER
    Medical condition: Recurrent or metastatic non-nasopharyngeal head and neck cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022444-20 Sponsor Protocol Number: 40-41200-98-9069 Start Date*: 2010-11-15
    Sponsor Name:ZonMW
    Full Title: PHASE I-II STUDY OF GEMCITABINE AND VALPROIC ACID PLUS VALGANCICLOVIR IN PATIENTS WITH ADVANCED NASOPHARYNGEAL CARCINOMA
    Medical condition: Patient has histological confirmed residual, recurrent or metastatic EBV-positive Nasopharynx carcinoma that has failed conventional curative treatments and deemed incurable, or patient refuses fur...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-004188-25 Sponsor Protocol Number: ASST_FARM_ONCO_P-ACC_2022 Start Date*: 2023-03-03
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: P-ACC Trial - Phase II, single arm, multicenter, open-label study of PARP inhibitors + cisplatin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma
    Medical condition: patients with recurrent and/or Metastatic Adenoid Cystic Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053231 Adenoid cystic carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073370 Adenoid cystic carcinoma of salivary gland PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053231 Adenoid cystic carcinoma PT
    24.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085951 Adenoid cystic carcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000454-38 Sponsor Protocol Number: CPDR001X2201 Start Date*: 2015-10-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progr...
    Medical condition: Moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-000066-22 Sponsor Protocol Number: BAY 43-9006 Start Date*: 2008-04-30
    Sponsor Name:Christie Hospital NHS Foundation Trust
    Full Title: A Phase 2 study of Sorafenib (BAY 43-9006) in patients with advanced salivary Adenoid Cystic Carcinoma
    Medical condition: advanced salivary adenoid cystic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053231 Adenoid cystic carcinoma PT
    9.1 10051975 Salivary gland carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001437-40 Sponsor Protocol Number: KO-TIP-007 Start Date*: 2019-03-08
    Sponsor Name:Kura Oncology, Inc.
    Full Title: The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM...
    Medical condition: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063569 Metastatic squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA) NO (Completed) BE (Completed) AT (Completed) NL (Completed) GR (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000309-64 Sponsor Protocol Number: AL-ACC-01 Start Date*: 2019-10-24
    Sponsor Name:Ayala Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-Label, Multi-Center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
    Medical condition: Adenoid cystic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053231 Adenoid cystic carcinoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002841-17 Sponsor Protocol Number: ASST-FARM_ONCO_TEPMEETCET-2022 Start Date*: 2023-04-07
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Phase 2, open-label, multicentre, single-arm study to evaluate the activity of the combination of EGFR inhibitors and c-MET inhibitors in patients with platinum-resistant head and neck squamous cel...
    Medical condition: in patients with platinum-resistant head and neck squamous cell carcinoma after relapse to immunotherapy “
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002206-52 Sponsor Protocol Number: CD-ON-MEDI4736-1108 Start Date*: 2012-12-05
    Sponsor Name:MedImmune
    Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006410-15 Sponsor Protocol Number: CRSV604A2201 Start Date*: 2007-05-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blinded, placebo-controlled, multiple dose study to assess the efficacy of intravenously administered RSV604 in immunocompromised adults with evidence of RSV infe...
    Medical condition: Respiratory Syncytial Virus (RSV) infection
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061603 Respiratory syncytial virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001523-69 Sponsor Protocol Number: V-CHANCE Start Date*: 2014-07-28
    Sponsor Name: Istituto Nazionale Tumori di Napoli - Fondazione "G. Pascale"
    Full Title: Preclinical and clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of head and neck
    Medical condition: Recurrent and/or metastatic squamous cell carcinoma of head and neck
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000461-23 Sponsor Protocol Number: CA209-627 Start Date*: 2017-03-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies
    Medical condition: Advanced/Metastatic malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001860-12 Sponsor Protocol Number: CMAK683X2101 Start Date*: 2017-01-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies
    Medical condition: Advanced malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001534-13 Sponsor Protocol Number: JAN13004-30 Start Date*: 2015-10-02
    Sponsor Name:SPHERIUM BIOMED S.L.
    Full Title: Phase IB-II clinical trial of melatonin oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing chemoradiation.
    Medical condition: Oral mucositis in patients with head and neck cancer undergoing chemoradiation
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022117 - Injury, poisoning and procedural complications 10037763 Radiation mucositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006804-34 Sponsor Protocol Number: CYP003 Start Date*: 2022-09-27
    Sponsor Name:Cytovation ASA
    Full Title: A Phase 1b/2a, Open-Label, Multi-Center Study of CyPep-1 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety of CyPep-1 in Patients With Advanced or Metastatic Head and Neck Squam...
    Medical condition: Advanced or metastatic: -Head and Neck Squamous Cell Carcinoma (HNSCC); -Melanoma; -Triple-Negative Breast Cancer (TNBC);
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 23 13:16:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA